Acid Reflux Control Aids Success in Barrett Esophagus Ablation

Using a standardized reflux management protocol, recurrence of intestinal metaplasia and dysplasia after complete eradication was low.

Poorly controlled gastroesophageal reflux is implicated as a risk factor for recurrence of Barrett esophagus (BE) after endoscopic eradication therapy (EET), recently estimated at an annual rate of 9.6% (NEJM JW Gastroenterol Nov 9 2016; [e-pub] and Am J Gastroenterol 2017; 112:87). However, the magnitude of the effect is unclear.

In a single-center observational study, researchers assessed complete eradication of intestinal metaplasia and its recurrence in 221 consecutive patients with BE who were managed with a standardized reflux therapy protocol. Participants were administered omeprazole (40 mg twice daily) prior and subsequent to EET with radiofrequency ablation (RFA); monitored for compliance; evaluated for symptom control; given reflu…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors